Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Semmelweis Egyetem has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner and is situated within 1 distinct art unit. This represents a focused prosecution profile for the institution at this time. ZEMAN, ROBERT A is the examiner responsible for this 1 pending office action. Because there are no other active matters, the outcome of this 1 pending office action will define the institution's current progress in the Biotechnology & Pharmaceuticals field.
The outcome of the institution's current prosecution depends entirely on the interaction with ZEMAN, ROBERT A. Since there is 1 pending office action, the applicant can focus all resources on addressing the specific concerns raised by this examiner. The involvement of 1 distinct art unit in the Biotechnology & Pharmaceuticals sector provides a stable administrative environment. Practitioners should tailor their responses to the specific technical standards of this 1 distinct art unit and the individual preferences of the examiner to maximize the chances of a favorable result. This focused strategy allows for a concentrated effort on a single technical matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZEMAN, ROBERT A | 1 | 54.3% | +27.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577867 | CORYNEBACTERIUM STRAINS FOR USE IN THE PREVENTION OF A VIRAL INFECTION | ZEMAN, ROBERT A | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18577867 | CORYNEBACTERIUM STRAINS FOR USE IN THE PREVENTION OF A VIRAL INFECTION | ZEMAN, ROBERT A | 1645 | §112 | Non-Final OA | — | Pending | Jan 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial